On December 23, the Boehringer Ingelheim-SEC Joint innovative incubator was inaugurated in Luohu District, Shenzhen. This marks the establishment of the first high-specification innovation platform in the Guangdong-Hong Kong-Macau Greater Bay Area (GBA), co-hosted by a multinational pharmaceutical company and an innovation center.
State-of-the-Art Facilities and Support for Biopharmaceutical Entrepreneurs
The incubator is equipped with top-notch scientific research equipment, advanced experimental instruments, and a high-quality office environment. It also offers comprehensive enterprise coaching and commercialization support. This initiative is open to entrepreneurs in the biopharmaceutical industry within the GBA and across the nation, providing high-end exclusive office spaces, complete experimental equipment, and comprehensive supporting services for innovative biopharmaceutical enterprises.
Enhancing the Biopharmaceutical Ecosystem in GBA
The Boehringer Ingelheim-SEC Joint Incubator aims to foster innovation and support the growth of biopharmaceutical companies, contributing to the development of the industry in the GBA. By providing access to cutting-edge facilities and comprehensive support services, the incubator is well-positioned to nurture the next generation of biopharmaceutical innovations.-Fineline Info & Tech
